Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Melegari, P. Scaglioni, J. Wands (1997)
The small envelope protein is required for secretion of a naturally occurring hepatitis B virus mutant with pre-S1 deletedJournal of Virology, 71
S. Stramer, S. Glynn, S. Kleinman, D. Strong, S. Caglioti, D. Wright, R. Dodd, M. Busch (2004)
Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing.The New England journal of medicine, 351 8
E. Hui, Yong Yi, S. Lo (1999)
Hepatitis B viral core proteins with an N-terminal extension can assemble into core-like particles but cannot be enveloped.The Journal of general virology, 80 ( Pt 10)
J. Seyec, P. Chouteau, Isabelle Cannie, C. Guguen-Guillouzo, P. Gripon (1999)
Infection Process of the Hepatitis B Virus Depends on the Presence of a Defined Sequence in the Pre-S1 DomainJournal of Virology, 73
J. Coste, H. Reesink, C. Engelfriet, S. Laperche, S. Brown, M. Busch, H. Cuijpers, R. Elgin, B. Ekermo, J. Epstein, O. Flesland, H. Heier, G. Henn, J. Hernández, I. Hewlett, C. Hyland, A. Keller, T. Krusius, S. Levičnik‐Stezina, G. Levy, Che Lin, A. Margaritis, L. Muylle, C. Neiderhauser, S. Pastila, J. Pillonel, Joelle Pineau, C. Poel, C. Politis, W. Roth, S. Sauleda, C. Seed, D. Sondag‐Thull, S. Stramer, M. Strong, E. Vamvakas, C. Velati, M. Vesga, A. Zanetti (2005)
Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003Vox Sanguinis, 88
S. Inaba, Akira Ito, Y. Miyata, H. Ishii, Shoko Kajimoto, Masatsugu Tanaka, A. Maruta, S. Saito, H. Yugi, M. Hino, K. Tadokoro (2006)
Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusionTransfusion, 46
G. Váradi, O. Svirsky, A. Nagler (2002)
Successful Major Surgical Recovery of a Patient following Haploidentical Stem Cell Transplantation for Chronic Myeloid Leukemia in Blast Crisis and AspergillosisActa Haematologica, 108
T. Tomono, H. Murokawa, K. Minegishi, R. Yamanaka, H. Lizuka, M. Miyamoto, S. Satoh, S. Nakahira, T. Murozuka, H. Emura, Y. Doi, H. Mine, S. Yokoyama, H. Ohnuma, T. Tanaka, A. Yoshikawa, K. Nishioka (2002)
Status of NAT screening for HCV, HIV and HBV: experience in Japan.Developments in biologicals, 108
C. Matsumoto, K. Tadokoro, Kayoko Fujimura, S. Hirakawa, S. Mitsunaga, T. Juji (2001)
Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repositoryTransfusion, 41
(2004)
Division of Blood Services of Japanese Red Cross Society. Transfusion-transmitted viral infection
M. Satake (2004)
Infectious Risks Associated with the Transfusion of Blood Components and Pathogen Inactivation in JapanInternational Journal of Hematology, 80
M. Kuhns, S. Kleinman, A. McNamara, B. Rawal, S. Glynn, M. Busch (2004)
Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti‐HBc: implications for future HBV screening policyTransfusion, 44
N. Yuki, T. Nagaoka, M. Yamashiro, K. Mochizuki, A. Kaneko, Keiji Yamamoto, M. Omura, K. Hikiji, Michio Kato (2003)
Long‐term histologic and virologic outcomes of acute self‐limited hepatitis BHepatology, 37
U. Staginnus, L. Corash (2004)
Economics of Pathogen Inactivation Technology for Platelet Concentrates in JapanInternational Journal of Hematology, 80
K. Li, T. Yamashiro, A. Sumie, H. Terao, K. Mifune, A. Nishizono (2001)
Hepatitis B virus harboring nucleotide deletions in the core promoter region and genotype B correlate with low viral replication activity in anti-HBe positive carriers.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 23 1-2
J. Tanaka, J. Kumagai, K. Katayama, Y. Komiya, M. Mizui, R. Yamanaka, Kou Suzuki, Y. Miyakawa, H. Yoshizawa (2004)
Sex- and Age-Specific Carriers of Hepatitis B and C Viruses in Japan Estimated by the Prevalence in the 3,485,648 First-Time Blood Donors during 1995–2000Intervirology, 47
J. Allain (2004)
Occult hepatitis B virus infection: implications in transfusionVox Sanguinis, 86
M. Berninger, Marlene Hammer, B. Hoyer, J. Gerin (1982)
An assay for the detection of the dna genome of hepatitis b virus in serumJournal of Medical Virology, 9
S. Preisler‐Adams, H. Schlayer, T. Peters, F. Hettler, Wolfgang Gerok, J. Rasenack (2005)
Sequence analysis of hepatitis B virus DNA in immunologically negative infectionArchives of Virology, 133
Thomas, C. Pasquinelli, S. Guilhot, F. Chisari (1994)
Hepatitis B virus persistence after recovery from acute viral hepatitis.The Journal of clinical investigation, 93 1
C. Hsia, R. Purcell, M. Farshid, P. Lachenbruch, M. Yu (2006)
Quantification of hepatitis B virus genomes and infectivity in human serum samplesTransfusion, 46
J. O’Riordan, P. Williams, J. Donnellan (2005)
HCV and HIV‐1 donor screening using nucleic acid amplification technique (NAT)Vox Sanguinis, 89
H. Mine, H. Emura, M. Miyamoto, T. Tomono, K. Minegishi, H. Murokawa, R. Yamanaka, A. Yoshikawa, K. Nishioka (2003)
High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan.Journal of virological methods, 112 1-2
J. Allain, P. Hewitt, R. Tedder, L. Williamson (1999)
Evidence that anti‐HBc but not HBV DNA testing may prevent some HBV transmission by transfusionBritish Journal of Haematology, 107
H. Iizuka, K. Ohmura, A. Ishijima, K. Satoh, Takeshi Tanaka, F. Tsuda, H. Okamoto, Y. Miyakawa, M. Mayumi (1992)
Correlation between Anti‐HBc Titers and HBV DNA in Blood Units without Detectable HBsAgVox Sanguinis, 63
Q. Meng, C. Wong, A. Rangachari, S. Tamatsukuri, M. Sasaki, E. Fiss, L. Cheng, T. Ramankutty, D. Clarke, H. Yawata, Y. Sakakura, Toru Hirose, C. Impraim (2001)
Automated Multiplex Assay System for Simultaneous Detection of Hepatitis B Virus DNA, Hepatitis C Virus RNA, and Human Immunodeficiency Virus Type 1 RNAJournal of Clinical Microbiology, 39
L. Barker, R. Murray (1972)
Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis—associated antigenThe American Journal of the Medical Sciences, 263
B. Rehermann, C. Ferrari, C. Pasquinelli, F. Chisari (1996)
The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte responseNature Medicine, 2
M. Busch, S. Glynn, S. Stramer, D. Strong, S. Caglioti, D. Wright, B. Pappalardo, S. Kleinman (2005)
A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donorsTransfusion, 45
S. Pogam, T. Yuan, G. Sahu, Soma Chatterjee, C. Shih (2000)
Low-Level Secretion of Human Hepatitis B Virus Virions Caused by Two Independent, Naturally Occurring Mutations (P5T and L60V) in the Capsid ProteinJournal of Virology, 74
K. Hu (2002)
Occult hepatitis B virus infection and its clinical implicationsJournal of Viral Hepatitis, 9
J. Katchaki, T. Siem, R. Brouwer, K. Brandt, M. Waart (1980)
Detection and significance of anti-HBc in the blood bank; preliminary results of a controlled prospective study.Journal of virological methods, 2 1-2
J. Bläckberg, K. Kidd‐Ljunggren (2000)
Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation.Journal of hepatology, 33 6
BACKGROUND: Japanese Red Cross (JRC) blood centers implemented anti‐hepatitis B core antigen (HBc) screening in 1989 and 50‐minipool (MP)‐nucleic acid testing (NAT) in 2000. A systematic lookback study has been conducted to determine the hepatitis B virus (HBV) transmission risk of donations drawn in the pre‐hepatitis B surface antigen (HBsAg) and/or MP‐NAT window phase and by donors with occult HBV infection. STUDY DESIGN AND METHODS: JRC blood centers have been storing aliquots of every blood donation since 1996. On the basis of the complete repository tube archives, all donations from repeat donors received from 1997 to 2004 were subjected to a lookback study. When repeat donors turned positive for HBV viral marker(s), repository tubes from their previous donations were tested for HBV with individual‐donation (ID)‐NAT. The frequency of ID‐NAT‐only–positive donations and the HBV transmission risk by the transfusion of those components were investigated. RESULTS: HBV ID‐NAT was performed on 15,721 repository tubes, and 158 tubes (1.01%) were found positive for the presence of HBV DNA. Of these 158 ID‐NAT‐only–positive donations, 95 (60%) were derived from carriers with low anti‐HBc titers. Of 63 patients transfused with ID‐NAT‐only–positive components, 12 (19%) proved to be infected with HBV. Only 1 of 33 components with low anti‐HBc titers could be identified as infectious, whereas 11 of 22 anti‐HBc–negative components proved to be infectious. None of the 16 identified hepatitis B surface antibody–positive components showed serologic evidence of infection. CONCLUSION: The clinically observed HBV infection risk caused by blood components from occult HBV carriers with low anti‐HBc titers who slip through the JRC screening system is more than 10‐fold lower than the transmission risk by donations in the pre‐HBsAg and/or MP‐NAT window phase.
Transfusion – Wiley
Published: Jul 1, 2007
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.